ATE287278T1 - Verwendung von propionyl-l-carnitin und acetyl-l- carnitin zur herstellung von arzneimittel mit antikrebs wirkung - Google Patents

Verwendung von propionyl-l-carnitin und acetyl-l- carnitin zur herstellung von arzneimittel mit antikrebs wirkung

Info

Publication number
ATE287278T1
ATE287278T1 AT99936973T AT99936973T ATE287278T1 AT E287278 T1 ATE287278 T1 AT E287278T1 AT 99936973 T AT99936973 T AT 99936973T AT 99936973 T AT99936973 T AT 99936973T AT E287278 T1 ATE287278 T1 AT E287278T1
Authority
AT
Austria
Prior art keywords
carnitine
acetyl
administration
anticancer agent
peripheral neuropathies
Prior art date
Application number
AT99936973T
Other languages
German (de)
English (en)
Inventor
Claudio Cavazza
Claudio Pisano
Loredana Vesci
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT98RM000511 external-priority patent/IT1302121B1/it
Priority claimed from IT1999RM000206 external-priority patent/IT1306124B1/it
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Application granted granted Critical
Publication of ATE287278T1 publication Critical patent/ATE287278T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT99936973T 1998-07-30 1999-07-27 Verwendung von propionyl-l-carnitin und acetyl-l- carnitin zur herstellung von arzneimittel mit antikrebs wirkung ATE287278T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT98RM000511 IT1302121B1 (it) 1998-07-30 1998-07-30 Associazione ad attivita' antineoplastica sostanzialmente priva deglieffetti tossici o collaterali causati dai farmaci antineoplastici
IT1999RM000206 IT1306124B1 (it) 1999-04-07 1999-04-07 Uso di alcanoil l-carnitine nella preparazione di medicamenti adattivita' antitumorale.
PCT/IT1999/000242 WO2000006134A2 (en) 1998-07-30 1999-07-27 Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity

Publications (1)

Publication Number Publication Date
ATE287278T1 true ATE287278T1 (de) 2005-02-15

Family

ID=26332128

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99936973T ATE287278T1 (de) 1998-07-30 1999-07-27 Verwendung von propionyl-l-carnitin und acetyl-l- carnitin zur herstellung von arzneimittel mit antikrebs wirkung

Country Status (11)

Country Link
US (5) US6610699B2 (enExample)
EP (1) EP1100589B1 (enExample)
JP (2) JP4703851B2 (enExample)
KR (1) KR100645980B1 (enExample)
AT (1) ATE287278T1 (enExample)
AU (1) AU764807B2 (enExample)
CA (1) CA2338638C (enExample)
DE (1) DE69923322T2 (enExample)
ES (1) ES2235499T3 (enExample)
PT (1) PT1100589E (enExample)
WO (1) WO2000006134A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
US20030199535A1 (en) * 1998-07-30 2003-10-23 Claudio Cavazza Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent
IT1302289B1 (it) * 1998-09-30 2000-09-05 Univ Catania Composizioni farmaceutiche ad attivita' antineoplastica
US20070037777A1 (en) * 2005-08-12 2007-02-15 Immunopath Profile, Inc. Lipid-containing compositions and methods of using them
DE19959546A1 (de) * 1999-12-09 2001-06-21 Rhone Poulenc Rorer Gmbh Pharmazeutische Zubereitung zur Behandlung von Tumorerkrankungen
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
PL361179A1 (en) * 2000-10-12 2004-09-20 Pharma Mar S.A. Treatment of cancers
US20050004012A1 (en) * 2001-10-19 2005-01-06 Ramon Mangues Use of aplidine for the treatment of pancreatic cancer
ITRM20020306A1 (it) 2002-05-31 2003-12-01 Sigma Tau Ind Farmaceuti Esteri in posizione 20 di camptotecine.
SI1603584T1 (sl) 2003-03-12 2009-02-28 Dana Farber Cancer Inst Inc Aplidin za zdravljenje multiple mieloma
US8314144B2 (en) * 2004-02-12 2012-11-20 Defiante Farmaceutica, S.A. Compounds having antitumor activity
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
ES2548432T3 (es) 2005-12-19 2015-10-16 Abbott Laboratories Uso de beta-hidroxi-beta-metilbutirato para modular el desequilibrio en la producción de citoquinas de tipo 1 y tipo 2
ITMI20070817A1 (it) 2007-04-19 2008-10-20 Farmacetika Ltd Composizione farmaceutica comprendente l-carnitina ed un agente antagonista dei recettori adenosinici di membrana, loro derivati e/o sali farmaceuticamente accettabili, e uso degli stessi nella preparazione di farmaci con effetto non tossico di inibi
CA2698129A1 (en) * 2007-08-31 2009-03-05 Kyushu University, National University Corporation Prophylactic or alleviating agent for peripheral nerve disorder induced by anti-cancer agent
US20120093809A1 (en) * 2008-12-01 2012-04-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of alkanoyl l-carnitine in combination with chemotherapeutic agents for the treatment of neoplasms
CN102060722B (zh) * 2009-05-01 2014-06-11 常州高新技术产业开发区三维工业技术研究所有限公司 一种含砷化合物及其制备方法和用途
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
RU2012125881A (ru) 2010-01-29 2014-03-10 Эбботт Лэборетриз Питательные эмульсии, содержащие бета-гидрокси-бета-метилбутират кальция (гмб кальция)
SG182808A1 (en) 2010-01-29 2012-09-27 Abbott Lab Aseptically packaged nutritional liquids comprising hmb
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
DE102011008016A1 (de) * 2011-01-06 2012-07-12 Johannes F. Coy Schokoladenmasse
KR20230116091A (ko) * 2012-06-27 2023-08-03 아마젠티스 에스에이 우롤리틴 또는 이의 전구체를 투여에 의한 자가포식향상 또는 장수 증가
ITPZ20130005A1 (it) * 2013-07-05 2015-01-06 Teodosio Antonio Ferrara Metabolismo energetico e omeostasi
RU2554776C1 (ru) * 2013-12-16 2015-06-27 Федеральное государственное бюджетное учреждение "Дальневосточный научный центр физиологии и патологии дыхания" СО РАМН Средство для коррекции нарушений в легочной ткани при цитостатическом воздействии
MX2017013383A (es) 2015-04-20 2017-12-07 Tolero Pharmaceuticals Inc Prediccion de respuesta a alvocidib mediante perfilado mitocondrial.
PL3298021T3 (pl) 2015-05-18 2019-11-29 Tolero Pharmaceuticals Inc Proleki alvocidibu o zwiększonej biodostępności
MX2018001289A (es) 2015-08-03 2018-04-30 Tolero Pharmaceuticals Inc Terapias de combinacion para el tratamiento del cancer.
KR101732483B1 (ko) * 2016-07-06 2017-05-24 한국 한의학 연구원 연교 추출물을 유효성분으로 함유하는 말초신경병증 예방, 개선 또는 치료용 조성물
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
AU2019391097B2 (en) 2018-12-04 2025-07-03 Sumitomo Pharma America, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
WO2020191326A1 (en) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Treatment of acute myeloid leukemia (aml) with venetoclax failure
CN115177608B (zh) * 2022-07-26 2023-12-05 南方医科大学南方医院 长链酰基肉碱类化合物在制备预防和/或治疗肝癌的药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267163A (en) * 1972-11-06 1981-05-12 Biocarn Limited Carnitine and its use in reducing cardiac toxicity
US4713370A (en) * 1972-11-06 1987-12-15 Felice Stephen L De Carnitine and its use in reducing cardiac toxicity and as a synergist with cytostats
IT1169460B (it) * 1982-09-13 1987-05-27 Sigma Tau Ind Farmaceuti Metodo e composizione per il trattamento di tumori
US4599352A (en) * 1984-03-01 1986-07-08 The United States Of America As Represented By The Department Of Health And Human Services Antineoplastic platinum (IV) complexes and compositions
IT1196564B (it) * 1986-08-04 1988-11-16 Sigma Tau Ind Farmaceuti Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche
US4936823A (en) * 1988-05-04 1990-06-26 Triangle Research And Development Corp. Transendoscopic implant capsule
IT1235153B (it) * 1988-11-15 1992-06-22 Sigma Tau Ind Farmaceuti Uso dell'acetil l-carnitina nel trattamento terapeutico della cataratta e composizioni farmaceutiche utili in tale trattamento
US5639737A (en) * 1991-11-04 1997-06-17 Co Enzyme Technology Ltd. Method and compositions for treating malignant tumors and inhibiting growth and metastases of malignant tumors
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
FR2727117A1 (fr) * 1994-11-18 1996-05-24 Geffard Michel Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
IT1275434B (it) * 1995-05-19 1997-08-07 Farmila Farma Milano Composizioni farmaceutiche e/o dietetiche ad attivita' antiossidante
IT1277898B1 (it) * 1995-08-03 1997-11-12 Mendes Srl Uso di amminoacidi basici, di acil derivati di amminoacidi basici e di loro sali farmaceuticamente accettabili per la profilassi di malattie
IT1283951B1 (it) * 1996-03-15 1998-05-07 Mendes Srl Uso della acetil l-carnitina o dei suoi sali farmacologicamente accettabili per il trattamento terapeutico o la profilassi di
DE19733305A1 (de) * 1997-08-01 1999-02-04 Asta Medica Ag Pharmazeutische Zusammensetzung enthaltend Ifosfamid und Carnitin

Also Published As

Publication number Publication date
US20080194683A1 (en) 2008-08-14
CA2338638A1 (en) 2000-02-10
US6610699B2 (en) 2003-08-26
DE69923322D1 (de) 2005-02-24
JP2010254717A (ja) 2010-11-11
US20090143464A1 (en) 2009-06-04
ES2235499T3 (es) 2005-07-01
WO2000006134A2 (en) 2000-02-10
AU764807B2 (en) 2003-08-28
US20010044465A1 (en) 2001-11-22
EP1100589A2 (en) 2001-05-23
KR100645980B1 (ko) 2006-11-14
JP2002521428A (ja) 2002-07-16
WO2000006134A3 (en) 2000-03-23
US20090137619A1 (en) 2009-05-28
AU5193599A (en) 2000-02-21
PT1100589E (pt) 2005-05-31
US20060258744A1 (en) 2006-11-16
CA2338638C (en) 2009-03-17
KR20010072093A (ko) 2001-07-31
JP4703851B2 (ja) 2011-06-15
HK1035677A1 (en) 2001-12-07
EP1100589B1 (en) 2005-01-19
DE69923322T2 (de) 2005-12-22

Similar Documents

Publication Publication Date Title
ATE287278T1 (de) Verwendung von propionyl-l-carnitin und acetyl-l- carnitin zur herstellung von arzneimittel mit antikrebs wirkung
ATE70439T1 (de) Verwendung von acetyl-l-carnitin zur herstellung eines medikamentes zur therapeutischen behandlung von peripheren neuropathien.
Brahmkshatriya et al. Clinical evaluation of Cissus quadrangularis as osteogenic agent in maxillofacial fracture: A pilot study
ATE292463T1 (de) L-carnitin oder ihre derivate und resveratrol oder ihre derivate zur vorbeugung und behandlung von kardiovaskulären erkrankungen, peripheren gefässkrankheit, peripheren diabetischen neuropathie und diese enthaltende pharmazeutische zusammensetzungen
RU2002127804A (ru) Лекарственная система для лечения осложнений, связанных с диабетом, и невропатии, и их применения
DE69434598D1 (de) Verwendung von Paclitaxel und seinen Derivaten zur Herstellung eines Medikaments für die Behandlung von Restenose
ATE267594T1 (de) Verwendung von albuminstabilisiertem paclitaxel zur herstellung eines arzneimittels zum behandeln von festen tumoren und das so erhaltene arzneimittel
CA2301057A1 (en) A method of administering liposomal encapsulated taxane
IS7102A (is) Taxól-eflandi efnasambönd
DE68911891D1 (de) Verwendung von Acetyl-L-carnitin zur Behandlung von Katarakt, sowie pharmazeutische Zusammensetzungen für eine derartige Behandlung.
DE69900207D1 (de) Verwendung von 11-(3-dimethylaminopropyliden)-6,11-dihydrodibenz[b,e]oxepin-2-essigsäure und deren pharmazeutisch annehmbaren salzen zur herstellung eines medikaments zur behandlung nicht-allergisch-bedingten augenentzündungen und zur prevention der okularen neovaskularisation
KR940018089A (ko) 내부조직의 방사선 손상에 대한 예방 및 처치방법
JP2022522798A (ja) スピルリナ抽出物の製造方法、スピルリナ抽出物を含む認知機能改善用薬学的組成物及び健康機能食品
EP1192949A4 (en) PREVENTIVE OR THERAPEUTIC DRUGS FOR TREATING FIBROSIS AND CONTAINING CHYMASE INHIBITORS AS ACTIVE INGREDIENTS
KR20100132489A (ko) 난소암을 치료하기 위하여 파클리탁셀을 포함하는 조합
JP5680412B2 (ja) レオヌリンの使用およびその組成物
AR041947A1 (es) Uso de acetil-l-carnitina o de una sal farmaceuticamente aceptable de la misma para la preparacion de un medicamento para prevenir y/o tratar las neuropatias perifericas inducidas por la administracion de un agente anticancer que induce neuropatias perifericas
CN1299278A (zh) 血管生成抑制
PL200928B1 (pl) Zastosowanie kwasu α-liponowego lub jego pochodnych do wytwarzania leku do zapobiegania albo leczenia migreny
EP1033133A4 (en) COMPOSITION FOR TREATING DIABETES AND METHOD FOR TREATING DIABETES
DE345883T1 (de) Verwendung von dapiprazol zur herstellung eines arzneimittels zur verhinderung des toleranzentwicklung bei der analgetischen behandlung mit morphin.
CN1195542C (zh) 肝病保护剂
CN101068548B (zh) 用于减少、稳定富含脂质的斑块和/或防止富含脂质的斑块破裂的方法
KR20210097487A (ko) 후코이단을 포함하는 수면장애 예방, 개선 또는 치료용 조성물
ATE77754T1 (de) Zusammensetzungen zur behandlung von gehirntumoren.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1100589

Country of ref document: EP